Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Senti Bio Awarded $8 Million Grant from California Institute for Regenerative Medicines for Clinical Development of Logic Gated CAR-NK Cell Therapy
Contract Type
partnership
Description
Senti Biosciences, Inc. (Nasdaq: SNTI) has announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia.
Related People
Agreement Insights
What this usually meansSenti Biosciences signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.